查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971755

治療診斷學市場分析及預測（至2035年）：依類型、產品類型、服務、技術、組件、應用、最終使用者、設備、流程分類

Theranostics Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Device, Process
出版日期: | 出版商: Global Insight Services | 英文 397 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，治療診斷學市場規模將從2024年的36億美元成長至118億美元，複合年成長率約為12.6%。治療診斷學市場將治療和診斷功能整合到單一平台，從而實現個人化治療策略。這種創新方法將標靶治療與診斷影像或生物標記相結合，以提高治療效果並監測治療反應。在分子成像、奈米技術和生物標記發現等領域取得進展的推動下，隨著精準醫療的日益普及，治療診斷學市場預計將迎來顯著成長。癌症發病率的上升和對個人化醫療解決方案需求的成長進一步推動了市場發展，為製藥和診斷行業的相關人員創造了巨大的成長機會。

預計治療診斷學市場將迎來顯著成長，主要驅動力是診斷和治療在個人化醫療中的融合。放射性藥物是市場領導者，其中放射性同位素和放射性標記肽在增強標靶癌症治療方面發揮關鍵作用。緊隨其後的是影像學領域，包括PET和SPECT技術，這進一步證實了它們在精準疾病診斷中的重要性。由於癌症發病率的上升以及對標靶治療的需求，腫瘤學細分市場預計將呈現最高的成長率。心血管治療診斷是第二大成長領域，這主要得益於心臟影像造影劑技術的進步。製藥公司和診斷設備製造商之間日益密切的合作正在加速該領域的創新。此外，人工智慧與影像和診斷技術的融合正在提高治療診斷解決方案的準確性和效率。隨著患者和醫療服務提供者尋求更安全、更有效的治療方法，對微創手術的需求也進一步推動了市場成長。

市場區隔
類型 顯影劑、治療劑、放射性同位素、生物標記、奈米顆粒、小分子、抗體、胜肽、基因治療
產品 試劑盒、試劑、儀器、軟體、耗材、檢測系統、診斷設備、治療設備
服務 諮詢、維護、安裝、培訓、數據分析、遠端監控
科技 聚合酶次世代定序（NGS）、免疫檢測分析、質譜分析、微陣列、流式細胞技術、液態生物檢體
成分 硬體、軟體和服務
應用領域 腫瘤科、神經科、心臟科、感染疾病、內分泌科、消化科、肺科
最終用戶 醫院、診斷檢查室、研究實驗室、製藥公司、生技公司、學術機構
裝置 PET掃描儀、MRI掃描儀、CT掃描儀、超音波設備、伽馬攝影機
過程 體內、試管內

市場概況：

受創新定價策略和新產品湧現的推動，治療診斷學市場正經歷市場佔有率的動態變化。主要企業正利用先進技術，並透過具競爭力的定價來提升產品的可及性和普及度。不斷湧入市場的新產品反映了強大的開發平臺，旨在滿足日益成長的個人化醫療需求。這一趨勢支持了該行業整合治療和診斷能力，並使其在精準醫療領域佔據領先地位的努力。競爭基準分析表明，策略聯盟和併購正在推動競爭優勢的形成。監管影響至關重要，嚴格的指導方針規範市場准入和產品開發。儘管市場由少數幾家主要企業主導，但新興企業也在創新和策略聯盟的推動下取得了顯著進展。北美和歐洲的法規結構尤其具有影響力，塑造市場動態，並創造了有利於成長的競爭環境。隨著技術進步和監管支持為持續擴張鋪平道路，該市場的未來前景光明。

主要趨勢和促進因素：

治療診斷學市場正經歷強勁成長，這主要得益於個人化醫療和標靶治療的進步。診斷和治療功能的整合是關鍵趨勢，能夠提高治療的精確度和有效性。隨著醫療系統致力於提供更個人化的患者照護，這種方法正日益受到重視。癌症和心血管疾病等慢性病的日益增加也是推動這一成長的重要因素。這些疾病需要創新的治療方案，進一步促進了治療診斷學的應用。此外，影像技術的進步提高了診斷的準確性，從而能夠更早發現和早期療育。伴隨診斷的興起也是一個顯著趨勢，有助於制定個人化的治療方案。治療診斷學產品監管核准的不斷增加反映出人們對其潛力的信心日益增強。隨著新興市場醫療基礎設施的完善和對先進療法需求的成長，這些市場正迎來盈利的機會。投資研發的企業有望抓住這些不斷擴大的機遇，並在不斷發展的治療診斷學領域確立領先地位。

限制與挑戰：

治療診斷學市場面臨許多顯著的限制與挑戰。其中一個主要挑戰是整合診斷和治療技術所帶來的高昂成本，這給醫療服務提供者和患者都帶來了沉重的經濟負擔。這種經濟壁壘限制了診療一體化技術的普及和廣泛應用，尤其是在新興市場。監管的複雜性也是一項重大挑戰。治療診斷學產品需要遵守複雜的核准流程，這會延遲其市場准入並增加研發成本。此外，缺乏跨區域的標準化法規結構進一步阻礙了全球市場的擴張。另一個挑戰是醫療專業人員對治療診斷學的認知和理解不足。這種知識差距可能會阻礙這些技術在臨床環境中的有效應用，並限制其潛在益處。此外，該領域技術的快速發展需要持續的研發投入。這種需求迫使企業在保持財務永續性的同時不斷創新。最後，治療診斷學應用中與病患資訊相關的資料隱私問題構成了一項重大障礙。確保強力的資料保護措施對於贏得病患信任和遵守監管規定至關重要。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 影像劑
    • 治療劑
    • 放射性同位素
    • 生物標記
    • 奈米顆粒
    • 低分子化合物
    • 抗體
    • 胜肽
    • 基因治療
  • 市場規模及預測：依產品分類
    • 成套工具
    • 試劑
    • 裝置
    • 軟體
    • 消耗品
    • 檢測系統
    • 診斷設備
    • 治療設備
  • 市場規模及預測：依服務分類
    • 諮詢
    • 維護管理
    • 安裝
    • 訓練
    • 數據分析
    • 遠端監控
  • 市場規模及預測：依技術分類
    • PCR
    • 次世代定序（NGS）
    • 免疫檢測
    • 質譜分析
    • 微陣列
    • 流式細胞技術
    • 液態生物檢體
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 神經病學
    • 心臟病學
    • 感染疾病
    • 內分泌學
    • 胃腸病學
    • 呼吸系統
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究所
    • 製藥公司
    • 生技公司
    • 學術機構
  • 市場規模及預測：依設備分類
    • PET掃描儀
    • 核磁共振掃描儀
    • CT掃描儀
    • 超音波設備
    • 伽馬攝影機
  • 市場規模及預測：依製程分類
    • In vivo
    • 體外

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Advanced Accelerator Applications
  • Theragnostics
  • Lantheus Holdings
  • NanoMab Technology
  • Radiomedix
  • Telix Pharmaceuticals
  • Blue Earth Diagnostics
  • Isotopia Molecular Imaging
  • Sofie Biosciences
  • Endocyte
  • Navidea Biopharmaceuticals
  • Cyclopharm
  • ImaginAb
  • OncoNano Medicine
  • Cerveau Technologies

第9章：關於我們

簡介目錄
Product Code: GIS34343

Theranostics Market is anticipated to expand from $3.6 billion in 2024 to $11.8 billion by 2034, growing at a CAGR of approximately 12.6%. The Theranostics Market encompasses the integration of therapeutic and diagnostic capabilities within a single platform, enabling personalized treatment strategies. This innovative approach combines targeted therapies with diagnostic imaging or biomarkers to enhance treatment efficacy and monitor therapeutic responses. As precision medicine gains traction, theranostics is poised for significant growth, driven by advancements in molecular imaging, nanotechnology, and biomarker discovery. The market is further propelled by increasing cancer prevalence and the demand for tailored healthcare solutions, promising substantial opportunities for stakeholders in the pharmaceutical and diagnostic sectors.

The Theranostics Market is poised for substantial growth, primarily driven by the integration of diagnostics and therapeutics in personalized medicine. Radiopharmaceuticals lead the market, with radioisotopes and radiolabeled peptides being pivotal in enhancing targeted cancer treatment. The imaging segment, comprising PET and SPECT technologies, follows closely, underscoring their importance in precise disease diagnosis. The oncology sub-segment is the top performer, driven by the rising prevalence of cancer and the need for targeted therapies. Cardiovascular theranostics, as the second highest performing sub-segment, is gaining momentum due to advancements in imaging agents for heart disease. Increasing collaboration between pharmaceutical companies and diagnostic firms is accelerating innovation in this field. Additionally, the integration of artificial intelligence in imaging and diagnostics is enhancing the accuracy and efficiency of theranostic solutions. The demand for minimally invasive procedures is further propelling market growth, as patients and healthcare providers seek safer and more effective treatment options.

Market Segmentation
TypeImaging Agents, Therapeutic Agents, Radioisotopes, Biomarkers, Nanoparticles, Small Molecules, Antibodies, Peptides, Gene Therapy
ProductKits, Reagents, Instruments, Software, Consumables, Assay Systems, Diagnostic Devices, Therapeutic Devices
ServicesConsultation, Maintenance, Installation, Training, Data Analysis, Remote Monitoring
TechnologyPCR, NGS, Immunoassays, Mass Spectrometry, Microarrays, Flow Cytometry, Liquid Biopsies
ComponentHardware, Software, Services
ApplicationOncology, Neurology, Cardiology, Infectious Diseases, Endocrinology, Gastroenterology, Respiratory
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Academic Institutions
DevicePET Scanners, MRI Scanners, CT Scanners, Ultrasound Devices, Gamma Cameras
ProcessIn Vivo, In Vitro

Market Snapshot:

The Theranostics market is witnessing a dynamic shift in market share, driven by innovative pricing strategies and a surge in new product launches. Key industry players are leveraging advanced technologies to offer competitive pricing, enhancing accessibility and adoption. The market is characterized by a continuous influx of novel products, reflecting a robust pipeline of developments aimed at meeting the growing demand for personalized medicine. This trend underscores the industry's commitment to integrating therapeutic and diagnostic capabilities, positioning itself at the forefront of precision healthcare. Competition benchmarking reveals a landscape marked by strategic alliances and mergers, enhancing competitive advantage. Regulatory influences are pivotal, with stringent guidelines shaping market entry and product development. The landscape is dominated by a few key players, yet emerging companies are making significant inroads, driven by innovation and strategic partnerships. Regulatory frameworks in North America and Europe are particularly influential, dictating market dynamics and fostering a competitive environment ripe for growth. The market's future is promising, with technological advancements and regulatory support paving the way for continued expansion.

Geographical Overview:

The theranostics market is witnessing notable expansion across various regions, each exhibiting unique growth dynamics. North America is at the forefront, driven by advanced healthcare infrastructure and significant investments in personalized medicine. The region's focus on integrating diagnostics and therapeutics enhances its market leadership. Europe follows closely, with strong regulatory support and a growing emphasis on precision medicine fostering a conducive environment for theranostics. Asia Pacific is rapidly emerging as a lucrative market, propelled by substantial investments in healthcare and technological advancements. Countries like China and India are spearheading growth, driven by increasing healthcare expenditures and a rising demand for personalized treatment solutions. Latin America and the Middle East & Africa are also showing promising growth potential. In Latin America, improving healthcare infrastructure and rising awareness of personalized medicine are key drivers. Meanwhile, the Middle East & Africa are recognizing the value of theranostics in addressing regional healthcare challenges and improving patient outcomes.

Key Trends and Drivers:

The theranostics market is experiencing robust growth, propelled by advancements in personalized medicine and targeted therapies. A key trend is the integration of diagnostic and therapeutic capabilities, which enhances treatment precision and efficacy. This approach is gaining traction as healthcare systems aim to provide more tailored patient care. Increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, is a significant driver. These conditions necessitate innovative treatment solutions, further fueling theranostics adoption. Additionally, advancements in imaging technologies are enhancing diagnostic accuracy, enabling early detection and intervention. The rise of companion diagnostics is another notable trend, supporting the development of personalized treatment regimens. Regulatory bodies are increasingly approving theranostic products, reflecting growing confidence in their potential. Emerging markets present lucrative opportunities as healthcare infrastructure improves and demand for advanced treatments rises. Companies investing in research and development are poised to capitalize on these expanding opportunities, positioning themselves as leaders in the evolving theranostics landscape.

Restraints and Challenges:

The Theranostics Market encounters several notable restraints and challenges. A primary challenge is the substantial cost associated with integrating diagnostic and therapeutic technologies, which imposes financial burdens on healthcare providers and patients alike. This financial barrier limits accessibility and adoption, particularly in emerging markets. Regulatory complexities also pose significant challenges. Navigating the intricate approval processes for theranostic products can delay market entry and increase development costs. Moreover, the lack of standardized regulatory frameworks across different regions further complicates global market expansion. Another challenge is the limited awareness and understanding of theranostics among healthcare professionals. This knowledge gap can impede the effective implementation of these technologies in clinical settings, restricting their potential benefits. Additionally, the rapid pace of technological advancements in the field requires continuous investment in research and development. This necessity places pressure on companies to innovate while managing financial sustainability. Lastly, data privacy concerns related to patient information in theranostic applications present a significant hurdle. Ensuring robust data protection measures is crucial to gaining patient trust and regulatory compliance.

Key Players:

Advanced Accelerator Applications, Theragnostics, Lantheus Holdings, NanoMab Technology, Radiomedix, Telix Pharmaceuticals, Blue Earth Diagnostics, Isotopia Molecular Imaging, Sofie Biosciences, Endocyte, Navidea Biopharmaceuticals, Cyclopharm, ImaginAb, OncoNano Medicine, Cerveau Technologies

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Process

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Imaging Agents
    • 4.1.2 Therapeutic Agents
    • 4.1.3 Radioisotopes
    • 4.1.4 Biomarkers
    • 4.1.5 Nanoparticles
    • 4.1.6 Small Molecules
    • 4.1.7 Antibodies
    • 4.1.8 Peptides
    • 4.1.9 Gene Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Kits
    • 4.2.2 Reagents
    • 4.2.3 Instruments
    • 4.2.4 Software
    • 4.2.5 Consumables
    • 4.2.6 Assay Systems
    • 4.2.7 Diagnostic Devices
    • 4.2.8 Therapeutic Devices
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation
    • 4.3.2 Maintenance
    • 4.3.3 Installation
    • 4.3.4 Training
    • 4.3.5 Data Analysis
    • 4.3.6 Remote Monitoring
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 PCR
    • 4.4.2 NGS
    • 4.4.3 Immunoassays
    • 4.4.4 Mass Spectrometry
    • 4.4.5 Microarrays
    • 4.4.6 Flow Cytometry
    • 4.4.7 Liquid Biopsies
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Neurology
    • 4.6.3 Cardiology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Endocrinology
    • 4.6.6 Gastroenterology
    • 4.6.7 Respiratory
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Diagnostic Laboratories
    • 4.7.3 Research Institutes
    • 4.7.4 Pharmaceutical Companies
    • 4.7.5 Biotechnology Companies
    • 4.7.6 Academic Institutions
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 PET Scanners
    • 4.8.2 MRI Scanners
    • 4.8.3 CT Scanners
    • 4.8.4 Ultrasound Devices
    • 4.8.5 Gamma Cameras
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 In Vivo
    • 4.9.2 In Vitro

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Device
      • 5.2.1.9 Process
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Device
      • 5.2.2.9 Process
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Device
      • 5.2.3.9 Process
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Device
      • 5.3.1.9 Process
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Device
      • 5.3.2.9 Process
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Device
      • 5.3.3.9 Process
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Device
      • 5.4.1.9 Process
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Device
      • 5.4.2.9 Process
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Device
      • 5.4.3.9 Process
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Device
      • 5.4.4.9 Process
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Device
      • 5.4.5.9 Process
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Device
      • 5.4.6.9 Process
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Device
      • 5.4.7.9 Process
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Device
      • 5.5.1.9 Process
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Device
      • 5.5.2.9 Process
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Device
      • 5.5.3.9 Process
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Device
      • 5.5.4.9 Process
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Device
      • 5.5.5.9 Process
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Device
      • 5.5.6.9 Process
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Device
      • 5.6.1.9 Process
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Device
      • 5.6.2.9 Process
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Device
      • 5.6.3.9 Process
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Device
      • 5.6.4.9 Process
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Device
      • 5.6.5.9 Process

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Theragnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Lantheus Holdings
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 NanoMab Technology
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Radiomedix
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Telix Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Blue Earth Diagnostics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Isotopia Molecular Imaging
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sofie Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Endocyte
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Navidea Biopharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cyclopharm
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 ImaginAb
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 OncoNano Medicine
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Cerveau Technologies
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us